SWOG clinical trial number
CTSU/E2607

A Phase II Trial of Dasatinib in KIT-Positive Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas

Closed
Phase
Published
Abbreviated Title
Ph II trial of dasatinib in KIT + patients with unresectable locally adv or Stage IV mucosal, acral and vulvovaginal melanomas
Status Notes
This study will permanently close to accrual effective 12/29/15.
Activated
12/01/2011
Participants
CTSU

Research committees

Melanoma

Treatment

Dasatinib

Eligibility Criteria Expand/Collapse

SWOG has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://ctsu.org/) for more information and registration procedures.

Publication Information Expand/Collapse

2017

A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral and vulvovaginal melanoma: a trial of the ECOG-ACRIN Cancer Research Group (E2607)

K Kalinsky;S Lee;K Rubin;DP Lawrence;AJ Iafrarte;DR Borger;K Margolin;M Leitao;A Tarhini;H Koon;A Pecora;A Jaslowski;GI Cohen;TM Kuzel;C Lao;JM Kirkwood Cancer Jul 15;123(14):2688-2697; 2017 Mar 23 [Epub ahead of print]

PMid: PMID28334439 | PMC number: PMC5498223

Other Clinical Trials

SWOG Clinical Trial Number
S2000
SWOG Clinical Trial Number
CTSU/EA6174